Literature DB >> 582496

Antepartum aminophylline treatment for prevention of the respiratory distress syndrome in premature infants.

E Hadjigeorgiou, S Kitsiou, A Psaroudakis, C Segos, D Nicolopoulos, D Kaskarelis.   

Abstract

The frequency of idiopathic respiratory distress (IRD) among premature offspring born of women who were given aminophylline before the thirty-fourth week of pregnancy was evaluated. Sixty-seven premature deliveries were included in the aminophylline group and 75 in the control group. The perinatal death rate was 7.1% in the aminophylline group and 17.9% in the control group (p less than 0.05). A statistically significant difference was noted between the aminophylline and control groups in the frequency of IRD which was three times lower (10%) in the aminophylline group than in the control group (29.5%) for the total of premature infants. If the time of rupture of membranes is taken into consideration, a significant decrease in the frequency of IRD following aminophylline administration is noted in the infants, whose mothers had ruptured membranes for more than 24 hours. No complications or side effects of aminophylline administration were noted in the mothers or their infants.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582496     DOI: 10.1016/0002-9378(79)90355-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

Review 1.  Fetal drug therapy.

Authors:  M I Evans; P G Pryde; A Reichler; M Bardicef; M P Johnson
Journal:  West J Med       Date:  1993-09

2.  Advances in respiratory distress syndrome.

Authors:  N R Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

Review 3.  Prenatal adverse effects of various drugs and chemicals. A review of substances of frequent concern to mothers in the community.

Authors:  M Bologa-Campeanu; G Koren; M Rieder; M McGuigan
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

4.  A Possible Association between Oral Aminophylline Treatment during Pregnancy and Skeletal Congenital Abnormalities.

Authors:  Andrew E Czeizel; Erzsébet Puhó; Zoltán Bártfai; Akos Somoskövi
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.